Posted: 18 November
ChulaCov19 BNA159 is a COVID-19 mRNA vaccine developed by Chulalongkorn University and produced by BioNet
• ChulaCov19 mRNA vaccine was found safe and immunogenic for primary immunization in clinical trials in Thailand.
• The Australian trial will evaluate the safety and immunogenicity of a booster dose of ChulaCov19 BNA159 mRNA vaccine in healthy volunteers.
• The collaborators of the trial are Chulalongkorn University, BioNet and Technovalia. Melbourne, 15th November 2022
Technovalia, Chulalongkorn University and BioNet announced that Human Research Ethics Committee (HREC) in Australia approved the phase 2 trial of ChulaCov19 BNA159 mRNA vaccine as a booster dose in adults.
Ethics approval is granted to commence a phase 2 trial after sharing satisfactory results of clinical safety and immunogenicity data of prior phase 1 and 2 studies of ChulaCov19 mRNA vaccine.
